Glucose Meter Manufacturing in European Union 2026: Industry Statistics & Trends

The glucose meter manufacturing industry in the European Union involves the production of electronic medical devices and diagnostic tools used for measuring blood glucose levels, encompassing traditional finger-stick systems and advanced continuous glucose monitoring (CGM) systems. The sector is shifting rapidly from conventional self-monitoring devices to connected, real-time digital health platforms to manage the rising prevalence of diabetes. According to official Eurostat data for the broader manufacturing class containing these devices, the EU production value reached a substantial baseline in recent years under strict internal market monitoring. Industry growth is heavily steered by tr

Industry snapshot

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Glucose Meter Manufacturing in European Union industry cover?

The glucose meter manufacturing industry within the European Union comprises the engineering, production, and calibration of instruments designed to monitor blood sugar levels. This covers traditional blood glucose meters that utilize disposable electrochemical test strips, as well as complex continuous glucose monitoring (CGM) systems featuring wearable subcutaneous sensors. Under the European standard classification system, these activities fall under the manufacturing of electronic medical and diagnostic apparatus.

• •Includes both in vitro diagnostic self-testing kits and wearable medical devices.
• •Classified officially within the EU under the NACE Rev. 2 economic framework.
• •Covers integrated components including electronic readers, sensors, and secure data transmitters.

Who operates in the industry and how is it structured?

The industry displays a highly concentrated structural format across the European Union, dictated by high barriers to entry and massive capital requirements for clinical validation. Production is dominated by a few well-established multinational medical technology corporations that maintain widespread manufacturing, assembly, or European distribution operations across member states. These large-scale operators utilize sophisticated supply chains to deliver both physical hardware and the proprietary software required to process glucose data safely.

• •Highly concentrated structure dominated by large multinational corporations with localized EU infrastructure.
• •Production is heavily dependent on secure, certified regional manufacturing facilities that meet EU cleanroom standards.
• •Requires deep integration with specialized component suppliers for biochemical enzymes and microelectronics.

What drives demand in the industry?

The primary catalyst for the industry is the growing prevalence of both Type 1 and Type 2 diabetes across the European population, creating a continuous need for monitoring solutions. Furthermore, public healthcare systems across the EU are increasingly expanding reimbursement pathways for advanced CGM devices to reduce long-term hospitalization costs. This structural shift toward proactive, data-driven disease management fuels a steady consumer demand for smart, connected devices.

• •Expanding diabetic patient demographics across all European Union member states.
• •Favorable reimbursement adjustments by public national health insurance funds for digital diabetes tech.
• •Clinical transition from legacy manual finger-prick testing to real-time, automated monitoring systems.

Who are the notable companies in the industry?

Competition in the EU market is intense and revolves around technological accuracy, sensor wear-life, and seamless software integration with smartphones. Prominent global medical device manufacturers operate dedicated corporate entities and production hubs within the EU to serve the single market efficiently. These corporations compete directly on intellectual property, product reliability, and secure cloud-based reporting systems.

• •Abbott Laboratories operates significant European distribution and compliance infrastructure, notably managing its FreeStyle Libre portfolio registered under EU public health databases.
• •F. Hoffmann-La Roche Ltd distributes its prominent Accu-Chek monitoring systems through extensive regional networks.
• •Ascensia Diabetes Care Holdings AG maintains active operations across Europe following its carve-out to manage the legacy Contour portfolio.
• •Dexcom, Inc. serves the European continent through established subsidiaries like Dexcom Deutschland GmbH, focusing exclusively on continuous glucose systems.

What are the recent trends and outlook?

The industry is undergoing a rapid technological evolution characterized by the absolute dominance of connected Internet of Medical Things (IoMT) systems. Modern glucose meters are increasingly built to transmit real-time telemetry to mobile applications, facilitating automated clinical evaluation reports. Moving forward, the outlook is strongly geared toward interoperability, where meters talk directly to automated insulin delivery pumps.

• •Mandatory integration of Unique Device Identifiers (UDI) across all product lines to ensure real-time traceability.
• •Rising adoption of 'eCGM' parameters demanding rigorous analytical and clinical performance across different sensor lots.
• •Accelerated development of cybersecurity protocols to safeguard wireless data transmissions under European privacy laws.

How is the industry regulated?

The regulatory landscape in the European Union is exceptionally stringent, governed legally by the In Vitro Diagnostic Regulation (EU 2017/746) and the Medical Devices Regulation (EU 2017/745). Traditional blood glucose monitors and test strips are generally categorized under Class C of the IVDR, requiring rigorous conformity assessments by Notified Bodies. Compliance requires exhaustive technical documentation, strict post-market clinical follow-up, and explicit CE marking before any device can be placed on the EU market.

• •Regulated strictly by Regulation (EU) 2017/745 (MDR) and Regulation (EU) 2017/746 (IVDR), which replaced older directives.
• •Devices must feature a physical CE mark validating safety and compliance with EU law before commercial distribution.
• •Economic operators are legally required to document and prove supply chain traceability for a minimum period of 10 years.

Government, statistical and trade sources used for this Claight analysis.

• European Commission Public Health Medical Devices Sector Documentation 2025 ·
• Eurostat NACE Rev. 2 Economic Classification Registry ·
• Official Journal of the European Union: Regulation (EU) 2017/745 and Regulation (EU) 2017/746 ·
• MedTech Europe Diabetes Sector Group Position Statements 2025